Helping clients meet their business challenges begins with an in-depth understanding of the industries in which they work. That’s why KPMG LLP established its industry-driven structure. In fact, KPMG LLP was the first of the Big Four firms to organize itself along the same industry lines as clients.

How We Work

We bring together passionate problem-solvers, innovative technologies, and full-service capabilities to create opportunity with every insight.

Learn more

Careers & Culture

What is culture? Culture is how we do things around here. It is the combination of a predominant mindset, actions (both big and small) that we all commit to every day, and the underlying processes, programs and systems supporting how work gets done.

Learn more

Accelerated Approval Reforms in 2023 Omnibus

Accelerated Approval Reforms Will Impact Drug Sponsors and FDA


On December 29, 2022, President Biden signed the Consolidated Appropriations Act, 2023 (“the Omnibus”) into law. In addition to providing federal funding for FY 2023, the Omnibus bill included several noteworthy healthcare-related provisions, such as reforms to the FDA Accelerated Approval Program. Section 3210 of the Omnibus “modernizes” the Accelerated Approval Program, which was established in 1992 and codified in 2012 to expedite approval of drugs that address a serious condition “associated with morbidity that has substantial impact on day-to-day functioning,” offer “meaningful advantage over available therapy,” and demonstrate an “effect on an endpoint that is reasonably likely to predict clinical benefit.” 

The reforms in the Omnibus attempt to address some of the most serious concerns of lawmakers, patient advocates, and other stakeholders about use of the program. Reforms include changes to the process for revoking accelerated approval, drug sponsor requirements, FDA requirements, and enforcement mechanisms. However, many questions remain about how aggressively the FDA will use its new authorities and how drug sponsors will respond to new post-approval trial requirements.

Dive into our thinking:

FDA Accelerated Approval Program Reforms included in the 2023 Omnibus

Download PDF

Explore more

Thank you!

Thank you for contacting KPMG. We will respond to you as soon as possible.

Contact KPMG

Use this form to submit general inquiries to KPMG. We will respond to you as soon as possible.

By submitting, you agree that KPMG LLP may process any personal information you provide pursuant to KPMG LLP's Privacy Statement.

An error occurred. Please contact customer support.

Job seekers

Visit our careers section or search our jobs database.

Submit RFP

Use the RFP submission form to detail the services KPMG can help assist you with.

Office locations

International hotline

You can confidentially report concerns to the KPMG International hotline

Press contacts

Do you need to speak with our Press Office? Here's how to get in touch.